|Dr. Jianmin Fang||Exec. Director, CEO & Chief Scientific Officer||無||無||1962|
|Dr. Daotian Fu||Pres||無||無||1962|
|Mr. Jia Li||CFO & Joint Company Sec.||無||無||1980|
|Dr. Ruyi He||Exec. Director, Chief Medical Officer & Head of Clinical Research||無||無||1961|
|Mr. Jian Lin||Exec. Director||無||無||1955|
|Ms. Pak Yu Tam A.C.I.S., A.C.S.||Joint Company Sec.||無||無||無|
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in the People's Republic of China and internationally. The company's products in various stages of development include Telitacicept (RC18) for use in the treatment of autoimmune diseases, such as systemic lupus erythematosus, neuromyelitis optica spectrum disorder, rheumatoid arthritis, IgA nephritis, SjÃ¶gren's syndrome, multiple sclerosis, and myasthenia gravis; and Disitamab Vedotin (RC48) and RC98 for use in the treatment of various cancers. It is also developing RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; and RC88, which is in Phase 1 clinical trials for use in the treatment of diabetic macular edema, as well as pre-clinical products, such as RC108, RC118, RC138, RC148, and RC158 to treat various solid tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.
截至 無 止，榮昌生物－Ｂ 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。